가려움증 치료제 시장(2026-2030년)

The global pruritus drugs market is forecasted to grow by USD 6792.0 mn during 2025-2030, accelerating at a CAGR of 7.2% during the forecast period. The report on the global pruritus drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of chronic systemic and dermatological diseases, robust clinical pipelines and advancements in targeted biologic therapies, strategic licensing agreements and high value acquisitions expanding global reach.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global pruritus drugs market is segmented as below:

By Application

• Hematologic pruritus
• Oncological pruritus
• Renal pruritus
• Endocrine pruritus
• Cholestatic pruritus

By Route Of Administration

• Oral
• Topical
• Injectable
• Others

By End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the accelerated shift toward nonsteroidal topical innovations as one of the prime reasons driving the global pruritus drugs market growth during the next few years. Also, strategic expansion of targeted biologics into idiopathic and unexplained itch syndromes and rising prominence of precision therapeutics for systemic and renal pruritus management will lead to sizable demand in the market.

The report on the global pruritus drugs market covers the following areas:

• Global pruritus drugs market sizing
• Global pruritus drugs market forecast
• Global pruritus drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global pruritus drugs market vendors that include AbbVie Inc., Almirall SA, Bausch Health Companies Inc., Bristol Myers Squibb Co., CSL Ltd., Escient Pharmaceuticals, Galderma Group AG, Incyte Corp., Kiniksa Pharmaceuticals Ltd., Kissei Pharmaceutical Co. Ltd., LEO Pharma AS, Maruho Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Taiho Pharmaceutical Co. Ltd., Toray Industries Inc., Tvardi Therapeutics Inc., Vanda Pharmaceuticals Inc.. Also, the global pruritus drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Pruritus Drugs Market 2020 - 2024
  • Historic Market Size - Data Table on Global Pruritus Drugs Market 2020 - 2024 ($ million)
• 5.2 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.3 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.4 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Pruritus Drugs Market
• 6.2 Impact of geopolitical conflict on Global Pruritus Drugs Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Application

• 8.1 Market segments
• 8.2 Comparison by Application
• 8.3 Hematologic pruritus - Market size and forecast 2025-2030
• 8.4 Oncological pruritus - Market size and forecast 2025-2030
• 8.5 Renal pruritus - Market size and forecast 2025-2030
• 8.6 Endocrine pruritus - Market size and forecast 2025-2030
• 8.7 Cholestatic pruritus - Market size and forecast 2025-2030
• 8.8 Market opportunity by Application
  • Market opportunity by Application ($ million)

9 Market Segmentation by Route of Administration

• 9.1 Market segments
• 9.2 Comparison by Route of Administration
• 9.3 Oral - Market size and forecast 2025-2030
• 9.4 Topical - Market size and forecast 2025-2030
• 9.5 Injectable - Market size and forecast 2025-2030
• 9.6 Others - Market size and forecast 2025-2030
• 9.7 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Hospitals - Market size and forecast 2025-2030
• 10.4 Homecare - Market size and forecast 2025-2030
• 10.5 Specialty Clinics - Market size and forecast 2025-2030
• 10.6 Others - Market size and forecast 2025-2030
• 10.7 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Argentina - Market size and forecast 2025-2030
  • 12.6.3 South Africa - Market size and forecast 2025-2030
  • 12.6.4 UAE - Market size and forecast 2025-2030
  • 12.6.5 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.6 Turkey - Market size and forecast 2025-2030
  • 12.6.7 Colombia - Market size and forecast 2025-2030
  • 12.6.8 Egypt - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing prevalence of chronic systemic and dermatological diseases
  • Robust clinical pipelines and advancements in targeted biologic therapies
  • Strategic licensing agreements and high value acquisitions expanding global reach
• 13.2 Market challenges
  • High cost of advanced biologic therapies and stringent reimbursement policies
  • Underdiagnosis and lack of standardized diagnostic modalities
  • Complex health technology assessments and stringent regulatory pathways
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Accelerated shift toward nonsteroidal topical innovations
  • Strategic expansion of targeted biologics into idiopathic and unexplained itch syndromes
  • Rising prominence of precision therapeutics for systemic and renal pruritus management

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 15.5 Almirall SA
  • Almirall SA - Overview
  • Almirall SA - Business segments
  • Almirall SA - Key offerings
  • Almirall SA - Segment focus
  • SWOT
• 15.6 Bausch Health Companies Inc.
  • Bausch Health Companies Inc. - Overview
  • Bausch Health Companies Inc. - Business segments
  • Bausch Health Companies Inc. - Key offerings
  • Bausch Health Companies Inc. - Segment focus
  • SWOT
• 15.7 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.8 CSL Ltd.
  • CSL Ltd. - Overview
  • CSL Ltd. - Business segments
  • CSL Ltd. - Key news
  • CSL Ltd. - Key offerings
  • CSL Ltd. - Segment focus
  • SWOT
• 15.9 Galderma Group AG
  • Galderma Group AG - Overview
  • Galderma Group AG - Business segments
  • Galderma Group AG - Key offerings
  • Galderma Group AG - Segment focus
  • SWOT
• 15.10 Incyte Corp.
  • Incyte Corp. - Overview
  • Incyte Corp. - Product / Service
  • Incyte Corp. - Key news
  • Incyte Corp. - Key offerings
  • SWOT
• 15.11 Kiniksa Pharmaceuticals Ltd.
  • Kiniksa Pharmaceuticals Ltd. - Overview
  • Kiniksa Pharmaceuticals Ltd. - Product / Service
  • Kiniksa Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.12 Kissei Pharmaceutical Co. Ltd.
  • Kissei Pharmaceutical Co. Ltd. - Overview
  • Kissei Pharmaceutical Co. Ltd. - Business segments
  • Kissei Pharmaceutical Co. Ltd. - Key offerings
  • Kissei Pharmaceutical Co. Ltd. - Segment focus
  • SWOT
• 15.13 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.14 Regeneron Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc. - Overview
  • Regeneron Pharmaceuticals Inc. - Product / Service
  • Regeneron Pharmaceuticals Inc. - Key news
  • Regeneron Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.15 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 15.16 Taiho Pharmaceutical Co. Ltd.
  • Taiho Pharmaceutical Co. Ltd. - Overview
  • Taiho Pharmaceutical Co. Ltd. - Product / Service
  • Taiho Pharmaceutical Co. Ltd. - Key offerings
  • SWOT
• 15.17 Toray Industries Inc.
  • Toray Industries Inc. - Overview
  • Toray Industries Inc. - Business segments
  • Toray Industries Inc. - Key news
  • Toray Industries Inc. - Key offerings
  • Toray Industries Inc. - Segment focus
  • SWOT
• 15.18 Vanda Pharmaceuticals Inc.
  • Vanda Pharmaceuticals Inc. - Overview
  • Vanda Pharmaceuticals Inc. - Product / Service
  • Vanda Pharmaceuticals Inc. - Key news
  • Vanda Pharmaceuticals Inc. - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations